Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) saw a large decline in short interest in June. As of June 30th, there was short interest totaling 6,731 shares, a decline of 54.4% from the June 15th total of 14,757 shares. Based on an average trading volume of 70,886 shares, the short-interest ratio is currently 0.1 days. Approximately 0.2% of the company’s stock are sold short.

Exicure Stock Performance

NASDAQ:XCUR opened at $1.65 on Tuesday. The stock has a 50-day simple moving average of $2.67 and a 200-day simple moving average of $3.86. The stock has a market cap of $10.51 million, a P/E ratio of -1.06 and a beta of 3.61. Exicure has a 1 year low of $1.65 and a 1 year high of $9.50.

Exicure (NASDAQ:XCUR) last issued its earnings results on Friday, May 29th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($18.60) by $18.31.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 11th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.